Home » Stocks » BPMC

Blueprint Medicines Corporation (BPMC)

Stock Price: $107.26 USD 1.94 (1.84%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 5.98B
Revenue (ttm) 811.16M
Net Income (ttm) 333.22M
Shares Out 55.73M
EPS (ttm) 6.18
PE Ratio 17.36
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $107.26
Previous Close $105.32
Change ($) 1.94
Change (%) 1.84%
Day's Open 105.21
Day's Range 105.21 - 108.12
Day's Volume 163,865
52-Week Range 43.29 - 108.51

More Stats

Market Cap 5.98B
Enterprise Value 5.31B
Earnings Date (est) Mar 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 55.73M
Float 54.91M
EPS (basic) 5.77
EPS (diluted) 6.18
FCF / Share 6.54
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.76%
FCF Yield 6.03%
Payout Ratio n/a
Shares Short 3.45M
Short Ratio 8.14
Short % of Float 6.28%
Beta 0.95
PE Ratio 17.36
Forward PE n/a
P/FCF Ratio 16.58
PS Ratio 7.37
PB Ratio 4.45
Revenue 811.16M
Operating Income 325.29M
Net Income 333.22M
Free Cash Flow 360.58M
Net Cash 671.19M
Net Cash / Share 12.04
Gross Margin -32.66%
Operating Margin 40.10%
Profit Margin 41.10%
FCF Margin 44.45%
ROA 17.71%
ROE 36.29%
ROIC 49.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (15)

Buy 10
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$114.93*
(7.15% upside)
Low
81.0
Current: $107.26
High
146.0
Target: 114.93
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue66.5144.5221.4327.7711.40--
Revenue Growth49.39%107.79%-22.85%143.61%---
Gross Profit66.5144.5221.4327.7711.40--
Operating Income-361-247-151-72.58-51.64-39.73-21.00
Net Income-348-237-148-72.50-52.77-40.29-20.91
Shares Outstanding47.8343.8737.7927.4918.241.421.02
Earnings Per Share-7.27-5.39-3.92-2.64-3.07-32.41-23.43
Operating Cash Flow-278-175-120-24.51-31.68-35.40-19.03
Capital Expenditures-14.01-12.68-15.51-2.35-4.88-0.70-0.26
Free Cash Flow-292-188-135-26.87-36.56-36.10-19.28
Cash & Equivalents48949967821516447.432.18
Total Debt95.95-1.524.077.349.042.86
Net Cash / Debt39349967621115738.39-0.69
Assets70854071628317949.934.14
Liabilities24312191.7769.7234.9212945.59
Book Value464419624213144-79.38-41.45
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Blueprint Medicines Corporation
Country United States
Employees 420
CEO Jeffrey W. Albers

Stock Information

Ticker Symbol BPMC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BPMC
IPO Date April 30, 2015

Description

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.